Drug name - Brilinta

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(2 years from now)

CN1334816A ASTRAZENECA Novel Triazolo (4-D) Pyrimidine Compounds
Dec, 2019

(2 years ago)

CN1128801C ASTRAZENECA Novel Triazolo (4-D) Pyrimidine Compounds
Dec, 2019

(2 years ago)

IN200701115P3 ASTRAZENECA Compound Of Formula (Ii)
Dec, 2019

(2 years ago)

IN209907B ASTRAZENECA A Triazolo [4,5-D] Pyrimidine Compound Of Formula ( I )
Dec, 2019

(2 years ago)

IN238424B ASTRAZENECA A Triazolo [4,5-D]Pyrimidine Compound Of Formula (Ii)
Dec, 2019

(2 years ago)

IN200100577P3 ASTRAZENECA A Triazolo [4,5-D] Pyrimidine Compound Of Formula ( I )
Dec, 2019

(2 years ago)

EP1386921A1 ASTRAZENECA Intermediates For The Preparation Of Anti-Thrombotic 4H-Cyclopenta-1,3-Dioxol Derivatives
Dec, 2019

(2 years ago)

EP1386917A1 ASTRAZENECA Intermediates For The Preparation Of Certain Triazolopyrimidines As P2T Antagonists
Dec, 2019

(2 years ago)

EP1386917B1 ASTRAZENECA Intermediates For The Preparation Of Certain Triazolopyrimidines As P2T Antagonists
Dec, 2019

(2 years ago)

EP1386921B1 ASTRAZENECA Intermediates For The Preparation Of Anti-Thrombotic 4H-Cyclopenta-1,3-Dioxol Derivatives
Dec, 2019

(2 years ago)

EP1135391B1 ASTRAZENECA Novel Triazolo(4,5-D)Pyrimidine Compounds
Dec, 2024

(2 years from now)

EP1135391A1 ASTRAZENECA Novel Triazolo(4,5-D)Pyrimidine Compounds
Dec, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425934 ASTRAZENECA Pharmaceutical compositions Apr, 2030

(7 years from now)

US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction Jan, 2036

(13 years from now)

Drugs and Companies using TICAGRELOR ingredient

Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
60MG TABLET;ORAL Prescription
90MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.